INmune Bio, Inc.
INMB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $28 | $33 | $19 | $21 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $2 | $1 | $1 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $3 | $1 | $0 | $0 |
| Total Curr. Assets | $31 | $36 | $21 | $23 |
| Property Plant & Equip (Net) | $1 | $1 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $17 | $17 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $2 | $1 | $0 | $0 |
| Total NC Assets | $3 | $2 | $17 | $17 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $33 | $38 | $38 | $40 |
| Liabilities | – | – | – | – |
| Payables | $0 | $8 | $7 | $7 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $7 | $1 | $0 | $1 |
| Total Curr. Liab. | $7 | $9 | $8 | $7 |
| LT Debt | $1 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $1 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $1 | $0 | $0 | $0 |
| Total Liabilities | $8 | $9 | $8 | $7 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$204 | -$197 | -$173 | -$163 |
| AOCI | -$1 | -$1 | -$1 | -$1 |
| Other Equity | $230 | $0 | $0 | $0 |
| Total Equity | $25 | $29 | $30 | $32 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $33 | $38 | $38 | $40 |
| Net Debt | -$27 | -$33 | -$19 | -$21 |